In a research report issued today, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Bluebird Bio (NASDAQ:BLUE) with a Buy rating and a $50 price target, …
In a research note issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on shares of Prosensa Therapeutic (NASDAQ:RNA) with a $17 price target, which represents a …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Cell Therapeutics (NASDAQ:CTIC) and raised his price target …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target …
In a research report issued yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on NeoGenomics Inc. (NASDAQ:NEO) with a $7 price …
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on PTC Therapeutics (NADSAQ:PTCT) with a $43 price …
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on PTC Therapeutics (NASDAQ:PTCT) with a $43 price …
In a research report released today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Pharma (NASDAQ:NKTR) with a $21 price …
